small molecule

TRIESENCE

TRIAMCINOLONE ACETONIDE

Loss of exclusivityDecember 2029latest FDA-listed patent expiry
CompanyHARROW EYE LLC

Drug detail

Brand nameTRIESENCE
Active ingredientTRIAMCINOLONE ACETONIDE
Strength40MG/ML (40MG/ML)
Dosage formINJECTABLE
RouteINTRAVITREAL
ModalitySmall molecule
FDA approvalNovember 2007
Marketing statusRX

Listed patents

PatentExpiresType
8128960December 2029product
8211880March 2029use U-1257

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TRIESENCE patent cliff — loss of exclusivity December 2029 | CliffBio